#USA #Toronto #Clinical Trials #Resonant Clinical #Bio-specimens

Resonant Clinical Solutions Unveils Comprehensive Asset Management Programs

Resonant Clinical Solutions ("Resonant"), a global leader in clinical solutions, has made a significant announcement during the ISBER 2026 International Biorepositories Summit held in Toronto. The company introduced a suite of asset management programs aimed at revolutionizing sample storage strategies for organizations within the life sciences sector. This launch is particularly timely as life sciences organizations are currently navigating the complexities of handling an increasing number of samples across various centers, contract research organizations (CROs), and suppliers.

The Need for Innovative Solutions

As clinical trials evolve and expand, the complexity involved in managing sample storage is rising. There’s a noticeable shift towards advanced modalities, including cell and gene therapies, which increases expectations around data integrity, chain of custody, and audit readiness. This evolution is compounded by ever-growing pressures on laboratory space and storage budgets, necessitating decisions regarding sample management—a critical aspect of clinical operations. Christophe Berthoux, CEO of Resonant Clinical Solutions, highlighted that research samples represent years of invaluable investment and irreplaceable science, yet decisions about their management are often driven by inertia rather than strategic planning.

Tailored Programs to Meet Client Needs

In response to these challenges, Resonant has developed three distinct programs designed to cater to the diverse asset management needs of biorepositories. The programs include:

1. Remote Asset Management (RAM): This program is tailored for organizations whose samples are housed in their own laboratories or freezers, consuming essential space and staff time allocated for research and development (R&D). Resonant dispatches biorepository specialists to the client’s facilities to assess the inventory and operational requirements. They ensure compliance with regulations while facilitating the transfer of samples to a secure Resonant biorepository at the right time. Services involve real-time inventory tracking, optimizing the management of samples while freeing laboratory space and alleviating associated costs.

2. Proactive Asset Management (PAM): This service benefits organizations with completed studies where samples are scattered. Resonant assists clients in identifying finished studies and consolidating retained samples. This is achieved by liaising with collaborative labs and CROs, compiling inventories, and organizing logistics towards secure long-term storage at Resonant’s facilities. The outcome is a validated, comprehensive inventory ready for audits and future planning.

3. Strategic Asset Management (SAM): This program is aimed at organizations contemplating a shift in their storage strategies—be it internalizing services or transitioning samples to another external provider. Resonant evaluates the costs of inventory and storage, providing a detailed breakdown of options, including equipment, personnel, and compliance risks. They effectively compare these costs against the operational and financial impacts of transferring samples, ultimately helping clients establish an optimized storage strategy.

Commitment to Client-Centric Solutions

Corey Stone, Vice President and General Manager of the Biorepository Division at Resonant, commented on the development of these tailored programs. The intention is to offer precise solutions that align with the unique situations of each client. By determining the most suitable program for their current circumstances, Resonant provides the necessary infrastructure, regulatory rigor, and expertise for optimal and reliable outcomes.

Availability and Future Engagements

The full suite of sample asset management programs is now available for clients. Interested parties can find detailed information on Resonant’s website or reach out directly via email at [email protected]. Resonant will also participate in the ISBER 2026, located at booth no. 14, to showcase their innovative offerings.

About Resonant Clinical Solutions

Resonant Clinical Solutions serves as a global collaborator providing comprehensive clinical solutions to life sciences organizations throughout the clinical supply chain and sample lifecycle. With over 850 employees across the U.S., the U.K., and Europe, Resonant manages more than 100 million research assets and has supported over 2,500 clinical trials while ensuring more than 20,000 shipments to client facilities. Their mission is to equip partners with holistic solutions aimed at simplifying the clinical supply chain and sample management, thereby allowing organizations to focus on their science and patients.

For additional details about Resonant and its comprehensive services, please visit Resonant Clinical’s website.